Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Myeong‐Jin Kim

Matched on ORCID iD 0000-0001-7949-5402; OpenAlex author ID A5036060341. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: A nationwide population-based cohort study. Co-author DOI 10.1016/j.diabet.2025.101605↗
  2. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy. Last author DOI 10.4143/crt.2023.586↗
  3. The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC. Co-author DOI 10.1007/s00109-023-02369-6↗
  4. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin … Co-author DOI 10.1080/15384047.2023.2272334↗
  5. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/cells12202509↗
  6. CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer. Co-author DOI 10.3390/ijms241612993↗
  7. Regional lymph node metastasis detected on preoperative CT and/or FDG-PET may predict early recurrence of pancreatic adenocarcinoma after curative resection. Last author DOI 10.1038/s41598-022-22126-y↗
  8. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Co-author DOI 10.3389/fphar.2022.934746↗
  9. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2017.404↗
  10. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles. Co-author DOI 10.1097/md.0000000000002168↗
  11. Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31822a68bc↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joon Seong Park · 5 shared papers, 2022–2023 · strength 0.85
  2. Hyeon Woong Kang · 5 shared papers, 2022–2023 · strength 0.85
  3. Woosol Chris Hong · 4 shared papers, 2022–2023 · strength 0.68
  4. Hyung Sun Kim · 4 shared papers, 2022–2023 · strength 0.66
  5. Da Eun Lee · 3 shared papers, 2022–2023 · strength 0.50
  6. Mi‐Suk Park · 3 shared papers, 2019–2024 · strength 0.46
  7. Chang Moo Kang · 4 shared papers, 2012–2024 · strength 0.40
  8. Seungmin Bang · 2 shared papers, 2022–2024 · strength 0.36
  9. Yun Sun Lee · 2 shared papers, 2023 · strength 0.34
  10. Yun Kyung Cho · 1 shared paper, 2025 · strength 0.30
  11. Chang Hee Jung · 1 shared paper, 2025 · strength 0.30
  12. Jinsil Seong · 2 shared papers, 2015–2024 · strength 0.26
  13. Hyun Kyung Yang · 1 shared paper, 2024 · strength 0.21
  14. Ho Kyoung Hwang · 2 shared papers, 2015–2022 · strength 0.20
  15. Jongman Yoo · 1 shared paper, 2023 · strength 0.17
  16. Seung‐seob Kim · 1 shared paper, 2022 · strength 0.15
  17. Hee Seung Lee · 1 shared paper, 2022 · strength 0.15
  18. Ja Kyung Yoon · 1 shared paper, 2022 · strength 0.15
  19. Jin Yong Lee · 1 shared paper, 2019 · strength 0.10
  20. Hye Jin Kim · 1 shared paper, 2019 · strength 0.10
  21. Si Young Song · 2 shared papers, 2012–2015 · strength 0.09
  22. Woo Jung Lee · 2 shared papers, 2012–2015 · strength 0.09
  23. Sung Hwan Lee · 1 shared paper, 2015 · strength 0.05
  24. Jae Bock Chung · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.